European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia - Hochhaus, A.; Baccarani, M.; Silver, R. T.; Schiffer, C.; Apperley, J. F.; Cervantes, F.; Clark, R. E.; Cortes, J. E.; Deininger, M. W.; Guilhot, F.; Hjorth-Hansen, H.; Hughes, T. P.; et al. (Leukemia, 2020)
Keywords: 631/67/1059/602; 692/699/1541/1990/283/1896; 96; 96/95; Aniline Compounds - therapeutic use; Antineoplastic Agents - therapeutic use; Cancer; Cancer Research; Chronic myeloid leukemia; Clinical Decision-Making; Clinical Medicine; Consensus Development Conferences as Topic; Critical Care Medicine; Dasatinib - therapeutic use; Diagnosis; Disease Management; Dosage and administration; Drug therapy; Enzyme inhibitors; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Fusion Proteins, bcr-abl - metabolism; Gene Expression; Hematologi; Hematology; Humans; Imatinib; Imatinib Mesylate - therapeutic use; Inhibitor drugs; Intensive; Internal Medicine; Intolerance; Kinases; Klinisk medicin; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality; Life expectancy; Life Expectancy - trends; Life Sciences; Life span; Medical and Health Sciences; Medical societies; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Monitoring, Physiologic; Myeloid leukemia; Nitriles - therapeutic use; Oncology; Patient outcomes; Polymerase chain reaction; Pregnancy; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase; Pyrimidines - therapeutic use; Quality of Life; Quinolines - therapeutic use; Remission; Review; Review Article; Survival Analysis; Targeted cancer therapy; Transplantation; Tyrosine; Italy